ImmuCell Corporation — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow
$483K
Free Cash Flow↑+258.1% +$506K
$310K
Investing Cash Flow↓-367.7% -$259K
$-329K
Financing Cash Flow↓-10.1% -$37K
$-404K
Capex↓-12.2% -$24K
$172K
Acquisitions
—
Stock-Based Comp↑+50.7% +$35K
$104K
Debt Issued
$2M
Debt Repaid↑+5.4% +$20K
$395K
D&A↑+6.0% +$40K
$709K
Δ Working Capital
—
SBC Allocated Expense↑+50.7% +$35K
$104K